
Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.
Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.
An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).
Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.